Safavi F, Thome R, Li Z, Zhang G, Rostami A
Neurol Neuroimmunol Neuroinflamm. 2020; 7(4).
PMID: 32371548
PMC: 7217662.
DOI: 10.1212/NXI.0000000000000729.
Tortorice K, Antonovich N
Fed Pract. 2020; 37(Suppl 1):S36-S42.
PMID: 32341635
PMC: 7182246.
Goldman M, Dwyer L, Coleman R, Sohn M, Stuve O
PLoS One. 2020; 15(2):e0228617.
PMID: 32045436
PMC: 7012426.
DOI: 10.1371/journal.pone.0228617.
Schweitzer F, Laurent S, Fink G, Barnett M, Hartung H, Warnke C
J Neurol. 2020; 268(7):2379-2389.
PMID: 32036423
PMC: 8217029.
DOI: 10.1007/s00415-019-09690-6.
Berger T, Brochet B, Brambilla L, Giacomini P, Montalban X, Vasco Salgado A
Mult Scler J Exp Transl Clin. 2019; 5(4):2055217319887191.
PMID: 31832225
PMC: 6891011.
DOI: 10.1177/2055217319887191.
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.
Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S
Ther Adv Neurol Disord. 2019; 12:1756286419836571.
PMID: 30967901
PMC: 6444778.
DOI: 10.1177/1756286419836571.
Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis.
Dickel H, Bruckner T, Hoxtermann S, Dickel B, Trinder E, Altmeyer P
J Eur Acad Dermatol Venereol. 2019; 33(5):893-905.
PMID: 30680823
PMC: 6593701.
DOI: 10.1111/jdv.15448.
Managing Risks with Immune Therapies in Multiple Sclerosis.
Forster M, Kury P, Aktas O, Warnke C, Havla J, Hohlfeld R
Drug Saf. 2019; 42(5):633-647.
PMID: 30607830
DOI: 10.1007/s40264-018-0782-8.
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu M
CNS Drugs. 2018; 32(10):963-970.
PMID: 30022464
DOI: 10.1007/s40263-018-0543-3.
Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation.
Wright K, Winkler M, Newton B, Sormani M, Okuda D
Neurol Neuroimmunol Neuroinflamm. 2017; 4(6):e397.
PMID: 28959705
PMC: 5614725.
DOI: 10.1212/NXI.0000000000000397.
Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.
Alroughani R, Farouk Ahmed S, Behbehani R, Al-Hashel J
Neurol Ther. 2017; 6(2):189-196.
PMID: 28780745
PMC: 5700902.
DOI: 10.1007/s40120-017-0080-x.
Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.
Chaves C, Ganguly R, Ceresia C, Camac A
Mult Scler J Exp Transl Clin. 2017; 3(2):2055217317702933.
PMID: 28607757
PMC: 5408504.
DOI: 10.1177/2055217317702933.
Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.
Zhovtis Ryerson L, Green R, Confident G, Pandey K, Richter B, Bacon T
Ther Adv Neurol Disord. 2016; 9(6):454-461.
PMID: 27800021
PMC: 5066529.
DOI: 10.1177/1756285616661929.
Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate.
Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz J
Neurol Neuroimmunol Neuroinflamm. 2016; 3(5):e274.
PMID: 27606353
PMC: 4996537.
DOI: 10.1212/NXI.0000000000000274.
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.
Linker R, Haghikia A
Ther Adv Chronic Dis. 2016; 7(4):198-207.
PMID: 27433310
PMC: 4935836.
DOI: 10.1177/2040622316653307.
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations.
Fox R, Chan A, Gold R, Phillips J, Selmaj K, Chang I
Neurol Clin Pract. 2016; 6(3):220-229.
PMID: 27347439
PMC: 4909524.
DOI: 10.1212/CPJ.0000000000000238.
Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
Zurawski J, Flinn A, Sklover L, Sloane J
J Neurol. 2016; 263(8):1511-7.
PMID: 27193310
DOI: 10.1007/s00415-016-8162-8.
[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].
Klotz L, Berthele A, Bruck W, Chan A, Flachenecker P, Gold R
Nervenarzt. 2016; 87(6):645-59.
PMID: 26927677
DOI: 10.1007/s00115-016-0077-1.
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.
Gross C, Schulte-Mecklenbeck A, Klinsing S, Posevitz-Fejfar A, Wiendl H, Klotz L
Neurol Neuroimmunol Neuroinflamm. 2016; 3(1):e183.
PMID: 26767188
PMC: 4701136.
DOI: 10.1212/NXI.0000000000000183.
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
Longbrake E, Naismith R, Parks B, Wu G, Cross A
Mult Scler J Exp Transl Clin. 2015; 1.
PMID: 26550483
PMC: 4636217.
DOI: 10.1177/2055217315596994.
